---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005546"
form_type: "8-K"
ticker: "SONM"
cik: "0001178697"
company_name: "DNA X, Inc."
filed_at: "2025-04-21T23:59:59+00:00"
generated_at: "2026-05-23T10:01:11.524037+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sonim adopts poison pill in response to Orbic's $4.00/share takeover proposal; accelerates executive RSU vesting

## Summary
- Adopted limited-duration stockholder rights agreement triggered at 15.5% ownership (20% for passive investors), expiring April 21, 2026.
- Response to unsolicited Orbic North America proposal to buy outstanding shares for $4.00 per share and Orbic's rapid accumulation.
- Accelerated vesting of all previously granted RSUs for 81 employees effective April 17, 2025, including CEO Peter Liu (63,604 RSUs), CFO Clay Crolius (33,922), and CCO Charles Becher (70,671).
- Rights include flip-in, flip-over, and exchange provisions; redeemable at $0.001 per right before an acquiring person emerges.
- Board created Series A Junior Participating Preferred Stock with economic terms similar to 1,000 shares of common per preferred share.

## SEC filing metadata
- accession: 0001641172-25-005546
- form_type: 8-K
- ticker: SONM
- cik: 0001178697
- company_name: DNA X, Inc.
- filed_at: 2025-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.03, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178697/000164117225005546/0001641172-25-005546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178697/000164117225005546/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005546
- JSON: https://secwatch.observer/filing/0001641172-25-005546.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.